no doubt, I can be a little overly dramatic sometimes - "will be a bust" Lol - the combo data and the market's reaction is what matters, nxt yr $30 (?) GL.
If Mrk/Amgen see 65% ORR in combo ...Oncs investment will be a bust. Big pharma will not be interested in electroporation. ...Oncs is falling waaay behind. Tvec combo H&N , ph3 mel. (!!)
I expect this will be no different than most trials - 1) listed on clin. 2) 'change' to recruiting 3) and FINALLY ..... Oncs p.r. "1st patient enrolled ......" - mid/late July ?
IRB approval two weeks ago - enrolling non responders only. I hope the phones started ringing ten days ago, "we (oncs) have approval, enrolling now, contact your patients," - My guess mid July.
"Interestingly, IL-12 also has anti-angiogenic properties which disrupts the tumors ability to maintain a proper blood supply" - .....two edged sword ? decreased blood supply and increased TIL's.
copphiggins, Your questions in this thread are the best I've seen, ever ! ha : ) I'm hoping you can contact Pierce directly - He would love to answer them.
Ict-107, Imuc vaccine.... I found the fail in the ph I abstract, sold before phase II results ......from the abstract ..[ discussion section]
." . .. this continues a predominant trend of poor correlation of immune and survival metrics in cancer vaccine trials. This may be due to inaccurate determination of clinically relevant immune responder status by ex vivo assays, but could also reflect local inhibition of peripherally activated immune effectors at the tumor site "
Inhibition of immune effectors at the tumor site - uh oh....I think the HR was 1. (epic fail)
- Yes, ICT is a 'vaccine', not IL-12 .....but microbiologists and bio investors know the science of cells is extremely complicated and not nearly understood.
The combo, fingers crossed .....would love to see at least one responder of the first three treated.
irish ...thnks for the reply - the no side effects argument does not hold water. Tempted to delete but that would cause the reply by briannajor to disappear. Can't have that, he's waaay smarter than me and investors need to read him. My other argument for fail - if it's too good to be true...it is too good to be true.....will leave that for another day Lol !
from my notes dated 12/5/14......obviously a conference call.
Question: When you show regression in the distal tumors, are they being biopsied specifically and checked for TIL'S ?
Answer: That's actually a good question ......but with regard to your specific question about distal lesions and the presence of TIL'S, that is something that with our phase 2B we will be addressing.
Here's another thing I've learned - It's what the company doesn't tell you that you have to consider. Are they really going to wait for the combo trial to check for an increase in tils in untreated tumors ? The expanded melanoma trial, began enrolling one year ago - It would make sense to biopsy untreated tumors. If no increase ......it will not be made public. I guarantee that.
good job,,,,,shutting up that cat is not easy.....your questions are excellent.....give me 20-30 mins ...more questions in line with yours lol
No side effects. This is my biggest worry. Twelve years of reading/investing in bio and I can tell everyone...cancer drugs with no side effects don't work. Read Yervoy or Keytruda ...rough stuff ! On a technicality, IL-12 is not really a 'drug'. - "An interleukin that is naturally produced by dendritic cells ...." -
Let's go for the 'quinella' : )
1) - the MCC trial, final data due....protocol update yesterday on clin. trials.
2) - expanded melanoma trial . . .*increased frequency of pIL-12.
3) - H&N active, with first patient enrolled recently.
4) - TNBC, 1st enrollment possibly next month.
5) - Combo, Keytruda + Oncosec pIL-12 , IRB approval.
* increased because of proven safety.
Recruiting Mar.13' _____ Fully enrolled June.15' - 34 patients in two years. Oncs kicked #$%$. Averaging more than one patient per month. The employees should be proud of this milestone, I am.
- Phase II study to assess the safety and antitumor activity of pIL-12. With a six month treatment trial design , open label . . ..... they're sitting on a well kept secret, . Let's hope it's good.
the (optimistic) weasl.
With no other 13G's filed .....It's possible one tute bought the remaining 1.4M shares (7%+), but using 'sleight of hand' lol ..they diversified. IE: Blackrock fund, Blackrock trust same address but listed separately as institutional owners of several bio's. Oncs did say two purchasers of private placement.
No hurry....bios hit lows consistently early Aug., today $1.95 - on the outside looking in has advantages. No bias, etc., free from the 'emotion' involved when adding or selling. Buying then. GLTA
Nice. Trial design and estimated enrollment, etc. There will be no p.r. - Wall street only cares about the 'first patient enrolled' news. They know data will follow.
" OncoSec has stated it will have a number of trials that will begin enrolling this quarter—three specifically—"
Two weeks to enroll 3 trials. ...hmm ....maybe H&N this quarter. . . . . . ?